Gladstone Institutes

02/25/2026

Gladstone president Deepak Srivastava is featured in Authority Magazine discussing how technology is transforming the future of medicine.

From stem cells and gene editing to AI-driven discovery, Srivastava shares how Gladstone researchers are working to move beyond treating disease to engineering real cures — and how bold, tech-powered science is accelerating that future.

This convergence of AI, stem cell biology, and gene editing means that we no longer have to accept our genetic destiny. For the first time…

02/25/2026

Kazuo Nakamura joined Gladstone as a student intern in the lab of Seth Shipman, where he set out to search for retrons—bacterial defense mechanisms that scientists can harness for genome editing.

What began as a teaching project quickly turned into real discovery.

02/24/2026

AI is transforming how we tackle the hardest problems in biomedicine.

The challenges scientists face are so complex that they’re nearly impossible to solve without advanced computational tools. AI helps uncover hidden patterns in massive datasets—patterns that can spark new hypotheses, reveal insights, and even predict what might happen next.

By narrowing down an astronomical number of possibilities to the most promising ones, AI allows researchers to work more efficiently and move potential treatments closer to reality, faster.

At Gladstone, AI isn’t hype—it’s helping power the next generation of discovery.

02/24/2026

Gladstone researcher Sukrit Silas is a 2026 Hypothesis Fund awardee. Silas is setting out to solve the longstanding challenge of predicting phage-bacteria compatibility. His project could transform how phages are harnessed to fight against antibiotic resistance.

The Hypothesis Fund enables scientists to take intelligent risks. To defy the predominant expectations in their field. To go after their big ideas.

02/22/2026

Alisa Dietl’s path to science spans countries, disciplines, and a deep commitment to understanding disease. She grew up in Munich, Germany, and completed her medical training in Innsbruck, Berlin, and New York City before returning to Munich to earn her PhD in oncology.

Today, Dietl brings her clinical perspective to her work as a postdoctoral researcher, where she is co-mentored by Karin Pelka and Alex Marson. Here, she focuses on how interactions between cancer and immune cells can be targeted to develop more effective cancer immunotherapies.

02/21/2026

PUMAS is more than a summer program—it’s a launchpad. From hands-on research to lifelong connections, our interns leave with skills, confidence, and a clearer vision for their future in STEM.

Read what past interns had to say about how the program shaped their paths, sharpened their skills, and expanded their futures.

Applications for PUMAS are currently open. Link in comments to learn more.

02/21/2026

Congratulations to Steve Finkbeiner, who was selected as the recipient of the 2026 Innovation Award by the Society for Laboratory Automation and Screening for his work on AI, robotics, and the thinking microscope.

Breaking exhibitor and attendance records in Boston, the SLAS hosted 419 exhibitors and more than 7,600 registrants from 47 countries at its 2026 International Conference and Exhibition, February 7-11.

02/20/2026

Nadia Roan, a pioneer in the fight against some of the world’s most persistent viruses, has been elected as a 2026 Fellow of the American Academy of Microbiology.

Roan has made great strides in understanding how persistent viruses including HIV cause disease and how immunity to viruses shapes human health.

02/20/2026

Lights, camera, science 🎬🔬

Go behind the scenes of an on-screen interview with Gladstone scientist Julia Kaye.

Julia studies neurodegenerative diseases like ALS, Parkinson’s, and Huntington’s—and collaborates with researchers across the country to analyze the genomes of thousands of ALS patients.

Her goal? To uncover patterns that could transform how we understand and treat ALS.

02/19/2026

A new study shows red blood cells act as hidden glucose sponges in low-oxygen conditions, explaining why people living at high altitude have lower diabetes rates and points to new treatments.

New study shows red blood cells act as hidden glucose sponges in low-oxygen conditions, explaining why people living at high altitude have lower diabetes rates and pointing toward new treatments.

02/19/2026

AI isn’t just the future—it’s transforming science today.

At Gladstone Institutes, our researchers are not only using artificial intelligence—they’re building cutting-edge AI platforms that are helping decode disease, uncover new therapeutic targets, and accelerate discoveries that could lead to life-saving treatments.

From predicting key genetic drivers of heart defects to developing models that reveal how disease begins at the cellular level, AI is reshaping how biomedical research is done.

02/18/2026

This month, we’re spotlighting Alisa Dietl, a postdoctoral researcher at Gladstone whose international clinical and scientific training fuels her work on breakthrough cancer immunotherapies.

At Gladstone, Alisa studies how the tumor microenvironment blocks immune responses and is developing innovative approaches to arm CAR T cells to overcome these barriers and attack solid tumors more effectively—bringing discovery one step closer to patient impact.

Her journey from clinical care to translational research exemplifies the mission of bridging science with real-world therapeutic solutions.

Alisa Dietl brings her international training and clinical perspective to Gladstone, where she works to engineer more effective cancer immunotherapies for solid tumors.